| Monte Rosa Therapeutics–1AB Media: public relations, 202009 service existent by 1AB Media |
2020-09-24 |
| Monte Rosa Therapeutics–Aisling Capital: investment, 202009 financing round Series B totalling $96m incl new + lead investor Aisling Capital |
2020-09-24 |
| Monte Rosa Therapeutics–Alphabet: investment, 202009 financing round Series B totalling $96m incl new + co-investor GV |
2020-09-24 |
| Monte Rosa Therapeutics–Amzak Health: investment, 202009 financing round Series B totalling $96m incl new + co-investor Amzak Health |
2020-09-24 |
| Monte Rosa Therapeutics–Cambridge Asset Management: investment, 202009 financing round Series B totalling $96m incl new + co-investor CAM |
2020-09-24 |
| Monte Rosa Therapeutics–Casdin Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Casdin Capital |
2020-09-24 |
| Monte Rosa Therapeutics–Cormorant Asset Managment: investment, 202009 financing round Series B totalling $96m incl new + co-investor Cormorant |
2020-09-24 |
| Monte Rosa Therapeutics–HBM: investment, 202009 financing round Series B totalling $96m incl new + co-investor HBM Healthcare Investments |
2020-09-24 |
| Monte Rosa Therapeutics–New Enterprise Associates: investment, 202009 financing round Series B totalling $96m incl existing + co-investor NEA |
2020-09-24 |
| Monte Rosa Therapeutics–SEVERAL: investment, 202009 financing round Series B $96m led by AIsling Capital |
2020-09-24 |
| Monte Rosa Therapeutics–Sixty Degree Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Sixty Degree Capital |
2020-09-24 |
| Monte Rosa Therapeutics–Versant Ventures: investment, 202009 financing round Series B totalling $96m incl existing + co-investor Versant Ventures |
2020-09-24 |
| AM-Pharma–Bellevue: investment, 202009 existent portfolio company of BB Pureos Bioventures LP |
2020-09-23 |
| Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund |
2020-09-23 |
| ImCheck Therapeutics–Bellevue: investment, 202009 existent portfolio company of BB Pureos Bioventures LP |
2020-09-23 |
| Jennewein Biotechnologie–Chr. Hansen: investment, 202009– acquisition €310m on debt-free basis ANNOUNCED |
2020-09-22 |
| Salvia BioElectronics–SEVERAL: investment, 202009 financing round Series A €21m co-led by Panakès Partners + Inkef Capital + SHS |
2020-09-22 |
| Salvia BioElectronics–SHS: investment, 202009 financing round Series A totalling €21m incl new + co-lead investor SHS |
2020-09-22 |
| Lava Therapeutics–Bellevue: investment, 202009 financing round Series C totalling $83m incl new + co-investor BB Pureos Bioventures |
2020-09-17 |
| Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures |
2020-09-17 |
| Novartis–BioNTech: investment, 202009– acquisition of Novartis GMP Biologics Manufacturing Site in Marburg by BioNTech |
2020-09-17 |
| Dinaqor–KWM Communications: public relations, 202009 service existent by KWM Communications |
2020-09-16 |
| Moderna–Cabinet Privé de Conseils: public relations, 202009 service existent CPC is Swiss media contact |
2020-09-16 |
| Evotec–BIOASTER: antiinfectives, 202009– collab research to establish tech + innovation hub in Lyon work started in early 2020 |
2020-09-14 |
| Boehringer–Click Therapeutics: digital therapeutics, 202009– collab ufpront+milestones >$500m + royalties ww dev+marketing CT-155 for schizophrenia |
2020-09-11 |
| Canopy Biosciences–Bruker: investment, 202009 acquisition €na of Canopy Biosciences LLC by Bruker Corp |
2020-09-11 |
| Oncomfort–SEVERAL: investment, 202009 financing round Series A €10m co-led by Debiopharm + Crédit Mutuel Innovation |
2020-09-09 |
| Boehringer–BiomX: biomarker discovery, 202009– collab discovery of microbiome-based biomarkers for IBD using XMarker platform |
2020-09-02 |
| Evotec–Univ Oxford: biobanking, 202009– collab €na granting Evotec access to QUOD biobank for multi-omics analyses for drug discovery |
2020-09-02 |
| BioVersys–SEVERAL: investment, 202009 financing round Series B CHF19m |
2020-09-01 |
| Helmholtz–Bruker: NMR spectrometer, 202009c supply 1.2 GHz NMR spectrometer with 28 Tesla to FZ Jülich |
2020-09-01 |
| Switzerland (govt)–Moderna: mRNA-based vaccines, 202009c– contract for supply of 4.5m doses of Covid-19 vaccine candidate mRNA-1273 |
2020-09-01 |
| Aimmune Therapeutics–Nestlé: investment, 202008– cash tender offer for all remaining shares at $34.5/share representing total equity value of $2.6b |
2020-08-31 |
| Semalytix–SEVERAL: investment, 202008 financing round Series A €4.3m co-led by btov + Fly Ventures |
2020-08-31 |
| Aignostics–Berlin (govt): investment, 202008 seed financing round totalling €5m incl co-investor VC Fonds Technologie der IBB |
2020-08-28 |
| Aignostics–Boehringer: investment, 202008 seed financing round totalling €5m incl lead investor BIVF |
2020-08-28 |
| Aignostics–Hessen (govt): investment, 202008 seed financing round totalling €5m incl co-investor Future Capital |
2020-08-28 |
| Aignostics–High-Tech Gründerfonds: investment, 202008 seed financing round totalling €5m incl co-investor HTGF |
2020-08-28 |
| Aignostics–SEVERAL: investment, 202008 seed financing round €5m led by BIVF + incl HTGF + IBB VC Fonds Technologie + Future Capital |
2020-08-28 |
| Triumvira Immunologics–Bayer: investment, 202008 financing round Series A totalling $55m incl new + co-lead investor Leaps by Bayer |
2020-08-27 |
| Triumvira Immunologics–SEVERAL: investment, 202008 financing round Series A $55m co-led by Leaps by Bayer + Northpond Ventures |
2020-08-27 |
| Freenome–SEVERAL: investment, 202008 financing round Series C $270m co-led by Bain Capital Life Sciences + Perceptive Advisors |
2020-08-26 |
| Univ Guelph–Bruker: NMR spectrometer, 202008 supply existent of 400 MHz NMR spectrometer + Fourier 80 benchtop NRM system |
2020-08-24 |
| Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares |
2020-08-19 |
| CureVac–Hopp Group: investment, 202008 private placement €100m at $16/share to DH-LT-Investments GmbH + affiliates |
2020-08-18 |
| Bayer–Hua Medicine: dorzagliatin, 202008– commercialisation agreement + strategic partnership in China |
2020-08-17 |
| F2G Ltd–Advent Venture Partners: investment, 202008 financing round totalling $60.8m incl exisiting investor Advent Life Sciences |
2020-08-12 |
| F2G Ltd–Cowen: investment, 202008 financing round totalling $60.8m incl new investor Cowen Healthcare Investments |
2020-08-12 |
| F2G Ltd–EMS (BR): investment, 202008 financing round totalling $60.8m incl exisiting investor Brace Pharma Capital |
2020-08-12 |
| F2G Ltd–Morningside: investment, 202008 financing round totalling $60.8m incl exisiting investor Morningside Ventures |
2020-08-12 |
| F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures |
2020-08-12 |
| F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors |
2020-08-12 |
| Atriva Therapeutics–High-Tech Gründerfonds: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor HTGF |
2020-08-11 |
| Atriva Therapeutics–Meneldor: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor Meneldor BV |
2020-08-11 |
| Atriva Therapeutics–SEVERAL: credit, 202008– convertible loan financing round €8.6m led by existing investors Meneldor + HTGF |
2020-08-11 |
| Bayer–Atomwise: AI-based drug discovery, 202008 collab existent |
2020-08-11 |
| Bayer–Linklaters: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer |
2020-08-11 |
| Bayer–Morgan Stanley: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Therapeutics by Bayer |
2020-08-11 |
| Kandy Therapeutics–Bayer: investment, 202008– acquisition $425m upfront + $450m developm milestones + triple digit $m sales milestones |
2020-08-11 |
| Kandy Therapeutics–Goldman Sachs: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Tx by Bayer |
2020-08-11 |
| Kandy Therapeutics–Goodwin Procter: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer |
2020-08-11 |
| CureVac–SEVERAL: investment, 202008 IPO $245.3m with 13.3m+2m common shares at $16/share at Nasdaq Global Market |
2020-08-10 |
| Immunic–SEVERAL: investment, 202008 underwritten public offering $90m+$13.5m with 5m+750k shares common stock at $18/share |
2020-08-10 |
| T-Knife–Andera Partners: investment, 202008 financing round Series A totalling €66m incl existing + co-investor Andera Partners |
2020-08-06 |
| T-Knife–Boehringer: investment, 202008 financing round Series A totalling €66m incl existing + co-investor BIVF |
2020-08-06 |
| T-Knife–RA Capital Management: investment, 202008 financing round Series A totalling €66m incl new + co-lead investor RA Capital |
2020-08-06 |
| T-Knife–SEVERAL: investment, 202008 financing round Series A €66m co-led by Versant Ventures + RA Capital |
2020-08-06 |
| T-Knife–Versant Ventures: investment, 202008 financing round Series A totalling €66m incl new + co-lead investor Versant Ventures |
2020-08-06 |
| GentiBio–Novartis: investment, 202008 seed financing round totalling $20m inbcl co-lead investor Novartis Venture Fund |
2020-08-05 |
| GentiBio–SEVERAL: investment, 202008 seed financing round $20m led by OrbiMed + Novartis Venture + RA Capital Management |
2020-08-05 |
| Matterhorn Biosciences–Versant Ventures: investment, 202008– seed financing $30m commitment from Versant Ventures |
2020-08-05 |
| NBE Therapeutics–Optimum Strategic Communications: public relations, 202008 service existent by Optimum |
2020-08-03 |
| Varian Medical Systems–Siemens: investment, 202008– acquisition $16.4b in cash of Varian Medical Systems Inc by Siemens Healthineers AG ANNOUNCED |
2020-08-02 |
| DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital |
2020-07-29 |
| Vesigen Therapeutics–Bayer: investment, 202007 financing round Series A totalling $28.5m incl co-lead investor Leaps by Bayer |
2020-07-22 |
| Vesigen Therapeutics–SEVERAL: investment, 202007 financing round Series A $28.5m co-led by Leaps by Bayer + Morningside Ventures |
2020-07-22 |
| Quantro Therapeutics–Boehringer: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes |
2020-07-21 |
| Quantro Therapeutics–Evotec: drug discovery services, 202007– supply of hit identification services by Evotec |
2020-07-21 |
| Quantro Therapeutics–Evotec: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes |
2020-07-21 |
| Quantro Therapeutics–MC Services: public relations, 202007 service existent by MC Services |
2020-07-21 |
| Quantro Therapeutics–SEVERAL: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes |
2020-07-21 |
| Tubulis–Bavaria (govt): investment, 202007 financing round Series A totalling €10.7m incl co-investor Bayern Kapital |
2020-07-21 |
| Tubulis–BioMedPartners: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor BioMedPartners |
2020-07-21 |
| Tubulis–BPCE: investment, 202007 financing round Series A totalling €10.7m incl co-investor Seventure Partners |
2020-07-21 |
| Tubulis–Germany (govt): investment, 202007 financing round Series A totalling €10.7m incl co-investor Coparion |
2020-07-21 |
| Tubulis–High-Tech Gründerfonds: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor HTGF |
2020-07-21 |
| Tubulis–Occident Group: investment, 202007 financing round Series A totalling €10.7m incl co-investor Occident Group |
2020-07-21 |
| Tubulis–SEVERAL: investment, 202007 financing round Series A €10.7m co-led by BioMedPartners + HTGF |
2020-07-21 |
| Tubulis–Trophic Communications: public relations, 202007 service existent by Trophic Communications |
2020-07-21 |
| TeleClinic–Zur Rose Group: investment, 202007– acquisition of TeleClinic GmbH for mid-double-digit million EUR price by Zur Rose Group |
2020-07-16 |
| Enancio–Illumina: acquisition, 202007 acquisition of Enancio by Illumina |
2020-07-14 |
| Anergis–Virometix: allergy immunotherapy, 202007– collab research study at HZI using SVLPs supported by TRANSVAC2 grant in house dust mite allergy |
2020-07-09 |
| CirQuest Labs–MLM Medical Labs: investment, 202007 acquisition of CirQuest Labs by MLM Medical Labs |
2020-07-08 |
| Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications |
2020-07-08 |
| Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties |
2020-07-08 |
| Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund |
2020-07-03 |
| Resolution Spectra Systems–Merck (DE): investment, 202007 acquisition €na of Resolution Spectra Systems by Merck |
2020-07-01 |
| Roche–Inveox: sample management software, 202007– collab digitization Vantage Workflow Solution for histopathology labs with Roche Diagnostics |
2020-07-01 |
| Waters–Heidrick & Struggles: recruitment services, 202007 supply service placement of Udit Batra as CEO of Waters |
2020-07-01 |
| CRISPR Therapeutics–SEVERAL: investment, 202006– public offering $450m+67.5m with 6.43m+964.3k common shares at $70/share |
2020-06-29 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Date![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
